AR013422A1 - UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA - Google Patents

UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA

Info

Publication number
AR013422A1
AR013422A1 ARP980104054A ARP980104054A AR013422A1 AR 013422 A1 AR013422 A1 AR 013422A1 AR P980104054 A ARP980104054 A AR P980104054A AR P980104054 A ARP980104054 A AR P980104054A AR 013422 A1 AR013422 A1 AR 013422A1
Authority
AR
Argentina
Prior art keywords
propute
polypeptide
lead
nucleic acid
complete
Prior art date
Application number
ARP980104054A
Other languages
English (en)
Spanish (es)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12155497A external-priority patent/IL121554A0/xx
Priority claimed from IL12163997A external-priority patent/IL121639A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of AR013422A1 publication Critical patent/AR013422A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/834—Urine; urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
ARP980104054A 1997-08-14 1998-08-14 UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA AR013422A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL12155497A IL121554A0 (en) 1997-08-14 1997-08-14 Interleukin-18 binding proteins their preparation and use
IL12163997A IL121639A0 (en) 1997-08-14 1997-08-27 Interleukin-18 binding proteins their preparation and use
IL12186097A IL121860A0 (en) 1997-08-14 1997-09-29 Interleukin-18 binding proteins their preparation and use
IL12213497A IL122134A0 (en) 1997-08-14 1997-11-06 Interleukin-18 binding proteins their preparation and use
IL12546398A IL125463A0 (en) 1997-08-14 1998-07-22 Interleukin-18 binding proteins their preparation and use

Publications (1)

Publication Number Publication Date
AR013422A1 true AR013422A1 (es) 2000-12-27

Family

ID=27517687

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980104054A AR013422A1 (es) 1997-08-14 1998-08-14 UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA
ARP070104104A AR062867A2 (es) 1997-08-14 2007-09-17 Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070104104A AR062867A2 (es) 1997-08-14 2007-09-17 Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la

Country Status (28)

Country Link
US (4) US6605280B1 (OSRAM)
EP (1) EP1003781B1 (OSRAM)
JP (1) JP4272348B2 (OSRAM)
KR (1) KR100687388B1 (OSRAM)
CN (1) CN1243021C (OSRAM)
AR (2) AR013422A1 (OSRAM)
AT (1) ATE443719T1 (OSRAM)
AU (1) AU755794B2 (OSRAM)
BG (1) BG65519B1 (OSRAM)
BR (1) BRPI9811940B8 (OSRAM)
CA (1) CA2298855C (OSRAM)
CY (1) CY1109664T1 (OSRAM)
CZ (1) CZ300818B6 (OSRAM)
DE (2) DE1003781T1 (OSRAM)
DK (1) DK1003781T3 (OSRAM)
EA (1) EA003675B1 (OSRAM)
EE (1) EE05538B1 (OSRAM)
ES (1) ES2149149T3 (OSRAM)
HU (1) HU226698B1 (OSRAM)
IL (5) IL121860A0 (OSRAM)
NO (1) NO327240B1 (OSRAM)
NZ (1) NZ502392A (OSRAM)
PL (1) PL206070B1 (OSRAM)
PT (1) PT1003781E (OSRAM)
SI (1) SI1003781T1 (OSRAM)
SK (1) SK287194B6 (OSRAM)
UA (1) UA75862C2 (OSRAM)
WO (1) WO1999009063A1 (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18-BINDING PROTEINS
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
DE60041432D1 (de) * 1999-11-16 2009-03-12 Hayashibara Biochem Lab Antikörper spezifisch für den Interleukin-18 Vorläufer
EP2332579A3 (en) 2000-02-10 2011-09-21 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
SK288032B6 (sk) * 2000-02-21 2012-12-03 Merck Serono Sa Use of IL-18 inhibitors for manufacture of medicament for treatment and/or prevention of alcoholic hepatitis
AU2005211606B2 (en) * 2000-05-05 2007-02-22 Inserm - Institut National De La Sante Et De La Recherche Medicale Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
MXPA02010895A (es) * 2000-05-05 2003-03-27 Applied Research Systems Uso de inhibidores de interleucina 18 para el tratamiento y/o prevencion de aterosclerosis.
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
JP4860897B2 (ja) * 2001-01-29 2012-01-25 メルク セロノ ソシエテ アノニム 心疾患の治療および／または予防のためのｉｌ−１８阻害剤の使用
UA85531C2 (uk) * 2001-05-16 2009-02-10 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Застосування il-18 інгібіторів для лікування або попередження пов'язаної з сепсисом дисфункції серця
EA006744B1 (ru) * 2001-05-25 2006-04-28 Арес Трейдинг С. А. Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
UA78516C2 (en) * 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
EP1487541B1 (en) * 2002-03-22 2008-11-19 Laboratoires Serono SA Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
EP1545578A4 (en) 2002-08-28 2010-07-07 Immunex Corp COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES
ES2416510T3 (es) * 2002-10-08 2013-08-01 Ares Trading S.A. Uso de una citocina capaz de unirse a IL 18BP y de inhibir la actividad de una segunda citocina
IL152232A0 (en) * 2002-10-10 2003-05-29 Yeda Res & Dev Promoter to il-18bp, its preparation and use
AU2004235595C1 (en) * 2003-04-30 2009-09-24 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
SI1622939T1 (sl) 2003-05-13 2012-06-29 Merck Serono Sa Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega
PT1689777E (pt) * 2003-11-05 2007-05-31 Ares Trading Sa Processo para a purificação da proteína de ligação a il-18
BRPI0416467A (pt) 2003-11-12 2007-03-06 Univ Colorado Regents ácido nucléico purificado, célula hospedeira, proteìna purificada, anticorpo, fragmento fab, e, métodos para induzir a produção de tnf alfa, para tratar um paciente, e para triagem para inibidores da il-32
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
HRP20070474T3 (en) * 2004-03-01 2007-11-30 Ares Trading S.A. Use of a serum-free cell culture medium for the production of il-18bp in mammalian cells
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
WO2006003134A1 (en) * 2004-06-29 2006-01-12 Ares Trading S.A. Process for the purification of il-18 binding protein
ES2385639T3 (es) 2005-06-03 2012-07-27 Ares Trading S.A. Producción de una proteína de unión a IL-18 recombinante
ATE530227T1 (de) * 2005-06-03 2011-11-15 Merck Serono Sa Verwendung von il-18bp-isoformen zur behandlung und/oder vorbeugung neurologischer entzündungskrankheiten
ATE529433T1 (de) * 2005-06-10 2011-11-15 Ares Trading Sa Verfahren zur reinigung eines il-18-bindenden proteins
CN101003812B (zh) * 2006-01-17 2011-01-05 温州医学院 一种用于制备重组人egf-il18融合蛋白的方法
US8133978B2 (en) 2006-05-25 2012-03-13 Glaxo Group Limited Humanised anti-interleukin-18 antibody
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
EP2941310A4 (en) * 2013-01-02 2016-08-24 Wilsa Inc METHOD AND DEVICE FOR CONDITIONING LIQUIDS
WO2015032932A1 (en) * 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
EP3265807A1 (en) 2015-03-05 2018-01-10 AB2 Bio SA Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023143535A1 (zh) * 2022-01-28 2023-08-03 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
US20250297018A1 (en) * 2022-03-15 2025-09-25 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用
CN114891125B (zh) * 2022-06-16 2023-04-11 广东医科大学 一种长效重组白细胞介素-18结合蛋白及其生产方法与应用
KR20250133728A (ko) 2023-01-06 2025-09-08 라센 테라퓨틱스, 인코포레이티드 항-il-18bp 항체
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
ES2213209T3 (es) 1996-11-15 2004-08-16 Kennedy Institute Of Rheumatology Supresion de tnfalfa e il-12 en terapia.
WO1998024804A2 (en) 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
DE998300T1 (de) 1997-03-18 2001-03-01 Basf Ag Zusammensetzungen zur modulation der empfänglichkeit für corticosteroiden
DE69834727T2 (de) 1997-08-01 2007-01-25 Serono Genetics Institute S.A. 5' ests für sekretierte proteine die in verschiedenen geweben expremiert werden
ATE495257T1 (de) 1997-08-01 2011-01-15 Merck Serono Biodevelopment 5' ests für sekretierte proteine, die in verschiedenen geweben exprimiert werden
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
ATE275422T1 (de) 1998-04-28 2004-09-15 Applied Research Systems Konjugate aus polyole und beta-interferon
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18-BINDING PROTEINS
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
WO2001019373A2 (en) 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids

Also Published As

Publication number Publication date
US6605280B1 (en) 2003-08-12
BRPI9811940B8 (pt) 2021-07-06
CA2298855C (en) 2014-05-27
HU226698B1 (en) 2009-07-28
US20060154294A1 (en) 2006-07-13
BRPI9811940A (pt) 2000-09-05
DE69841175D1 (de) 2009-11-05
US7799541B2 (en) 2010-09-21
US7101689B2 (en) 2006-09-05
US20100010200A1 (en) 2010-01-14
CA2298855A1 (en) 1999-02-25
NO20000700D0 (no) 2000-02-11
ES2149149T1 (es) 2000-11-01
DK1003781T3 (da) 2010-01-25
JP2001514876A (ja) 2001-09-18
EP1003781A1 (en) 2000-05-31
CZ2000490A3 (cs) 2000-08-16
WO1999009063A1 (en) 1999-02-25
AR062867A2 (es) 2008-12-10
EE05538B1 (et) 2012-04-16
HUP0003533A2 (hu) 2001-01-29
PL338647A1 (en) 2000-11-06
US20040037829A1 (en) 2004-02-26
NO20000700L (no) 2000-04-14
KR100687388B1 (ko) 2007-02-26
NO327240B1 (no) 2009-05-18
BG65519B1 (bg) 2008-10-31
ES2149149T3 (es) 2009-12-01
KR20010022900A (ko) 2001-03-26
EE200000073A (OSRAM) 2000-10-16
EA003675B1 (ru) 2003-08-28
BRPI9811940B1 (pt) 2011-10-04
CN1243021C (zh) 2006-02-22
PL206070B1 (pl) 2010-06-30
CZ300818B6 (cs) 2009-08-19
SK287194B6 (sk) 2010-03-08
EP1003781B1 (en) 2009-09-23
SI1003781T1 (sl) 2009-12-31
IL134523A0 (en) 2001-04-30
US8436148B2 (en) 2013-05-07
ATE443719T1 (de) 2009-10-15
UA75862C2 (uk) 2006-06-15
DE1003781T1 (de) 2001-01-11
EA200000216A1 (ru) 2000-08-28
IL121860A0 (en) 1998-02-22
HUP0003533A3 (en) 2003-08-28
HK1028773A1 (en) 2001-03-02
IL122134A0 (en) 1998-04-05
SK1762000A3 (en) 2000-09-12
PT1003781E (pt) 2009-10-26
IL134523A (en) 2011-09-27
CY1109664T1 (el) 2014-08-13
CN1267307A (zh) 2000-09-20
IL125463A0 (en) 1999-03-12
AU755794B2 (en) 2002-12-19
JP4272348B2 (ja) 2009-06-03
AU8746098A (en) 1999-03-08
BG104149A (bg) 2000-08-31
NZ502392A (en) 2002-12-20

Similar Documents

Publication Publication Date Title
AR013422A1 (es) UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA
UA42760C2 (uk) Спосіб спрямування клітинної імунної відповіді проти віл-інфікованої клітини ссавця,білковий мембранозв'язаний химерний рецептор,днк,яка кодує химерний рецептор,вектор,що її містить
BG101171A (en) Antibodies which bind to insect gut proteins and their use
DE69324359D1 (de) Verbessertes verfahren zur herstellung von endotoxinbindungsproteinen
NZ503343A (en) Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
ATE353362T1 (de) Neuartige ctla4/cd28 liganden und deren anwendungen
AP9901541A0 (en) Broad-spectrum delta-endotoxins.
ATE448246T1 (de) Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
DE68926882D1 (de) Plasmidvektor mit pectatlyase-signalsequenz
ES508813A0 (es) Metodo de expresion de un gen codificador de un polipeptido util en una coagulacion de la leche.
ATE313633T1 (de) Expressionsvektoren die für bispezifische proteine kodieren, und verfahren zur herstellung von biologisch-aktiven bispezifischen fusionsproteine in zellen von säugertieren
DK13788A (da) Fremgangsmaade til fremstilling af et polypeptid
ATE353365T1 (de) Neue b7-4 moleküle und deren verwendungen
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
MXPA01002592A (es) Polipeptidos de transmembrana y secretados y acidos nucleicos que codifican los mismos.
KR100468977B1 (ko) 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
DK111183A (da) Polypeptid omfattende aminosyresekvensen af et dyreinterferon, dna-sekvens, der koder for polypeptidet, replicerbart udtrykkelsesmedium, som kan udtrykke dna-sekvensen, og fremgangsmaade til fremstilling af polypeptidet
NO860421L (no) Sammensmeltet gen som koder for et hybridprotein.
ATE353964T1 (de) Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
ES2170051T3 (es) Procedimiento para la produccion de proteinas utilizando proteinas fusionadas de tipo cks.
DE69932644D1 (de) Menschliches Protein mit in vitro antiproliferativer Aktivität.
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet
ES2120409T3 (es) Nuevos vectores de expresion y metodos para la produccion de proteinas intracelulares.
DE59914878D1 (de) Neuer spannungsabhängiger kaliumkanal und seine verwendung zur entwicklung von therapeutika

Legal Events

Date Code Title Description
FG Grant, registration